NCT03037385: Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only patients with tumors that have RET-rearrangement/fusion mutation will be eligible for the expansion phase (Part 2)
Exclusions: Central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT03037385

Comments are closed.

Up ↑